Cat.No：GM-87985MAB
Product ：Anti-TNFSF13B(BAFF) hIgG1 Reference Antibody (Belibio)
Cat.No：GM-87985MAB
Product ：Anti-TNFSF13B(BAFF) hIgG1 Reference Antibody (Belibio)
GM-87985MAB-1mg 1 mg
GM-87985MAB-5mg 5 mg
GM-87985MAB-25mg 5 mg * 5 vials
GM-87985MAB-50mg 50 mg
GM-87985MAB-100mg 50 mg * 2 vials
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity >95% as determined by SDS-PAGE
Endotoxin <1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target TNFSF13B(BAFF)
Clone Belimumab
Alternative Names BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4
Source/Isotype Monoclonal Human IgG1(KDEL), Lambda2
Application /
Description BAFF (B-cell Activating Factor), also known as BLYS, CD257, TALL-1, THANK, and TNFSF20, is a member of the tumor necrosis factor superfamily, encoded by the TNFSF13B gene. Belimumab, a monoclonal antibody targeting BAFF, is marketed under the name Benlysta and is the first biologic globally approved for the treatment of systemic lupus erythematosus (SLE). Belimumab blocks the interaction of BAFF with its receptors (BAFF-R, TACI, and BCMA), thereby reducing B cell activation and the production of autoreactive antibodies.
Formulation phosphate-buffered solution, pH 7.2-7.4.
Cat.No：GM-87985MAB
Product ：Anti-TNFSF13B(BAFF) hIgG1 Reference Antibody (Belibio)
GM-87985MAB-1mg 1 mg
GM-87985MAB-5mg 5 mg
GM-87985MAB-25mg 5 mg * 5 vials
GM-87985MAB-50mg 50 mg
GM-87985MAB-100mg 50 mg * 2 vials
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity >95% as determined by SDS-PAGE
Endotoxin <1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target TNFSF13B(BAFF)
Clone Belimumab
Alternative Names BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4
Source/Isotype Monoclonal Human IgG1(KDEL), Lambda2
Application /
Description BAFF (B-cell Activating Factor), also known as BLYS, CD257, TALL-1, THANK, and TNFSF20, is a member of the tumor necrosis factor superfamily, encoded by the TNFSF13B gene. Belimumab, a monoclonal antibody targeting BAFF, is marketed under the name Benlysta and is the first biologic globally approved for the treatment of systemic lupus erythematosus (SLE). Belimumab blocks the interaction of BAFF with its receptors (BAFF-R, TACI, and BCMA), thereby reducing B cell activation and the production of autoreactive antibodies.
Formulation phosphate-buffered solution, pH 7.2-7.4.
